Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Other Non-Current Assets of $14.1 billion for Q1 2026, down 1.83% sequentially from $14.4 billion in Q4 2025, and up 22.29% YoY from $11.5 billion in Q1 2025.
Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Other Non-Current Assets data on file, last reported at $14.1 billion in Q1 2026.
- Quarterly Other Non-Current Assets rose 22.29% year-over-year to $14.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 billion (up 22.29% YoY) and the FY2025 annual result came in at $14.4 billion, up 25.88% from the prior year.
- Other Non-Current Assets slipped to $14.1 billion in Q1 2026 per JNJ's latest filing, from $14.4 billion in the prior quarter.
- The five-year high for Other Non-Current Assets was $27.2 billion in Q1 2023, with the low at $7.7 billion in Q2 2023.
- Average Other Non-Current Assets over 5 years is $12.3 billion, with a median of $11.4 billion recorded in 2024.
- The widest YoY moves for Other Non-Current Assets: up 166.61% in 2023, down 48.04% in 2023.
- Johnson & Johnson's Other Non-Current Assets stood at $8.6 billion in 2022, then surged by 64.09% to $14.2 billion in 2023, then slipped by 19.35% to $11.4 billion in 2024, then gained by 25.88% to $14.4 billion in 2025, then slipped by 1.83% to $14.1 billion in 2026.
- Business Quant data shows JNJ's Other Non-Current Assets at $14.1 billion in Q1 2026, $14.4 billion in Q4 2025, and $12.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.23 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.54 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 200.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 777.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 14.11 Bn |
| Dec 28, 2025 | 14.37 Bn |
| Sep 28, 2025 | 12.42 Bn |
| Jun 29, 2025 | 12.19 Bn |
| Mar 30, 2025 | 11.53 Bn |
| Dec 29, 2024 | 11.41 Bn |
| Sep 29, 2024 | 10.92 Bn |
| Jun 30, 2024 | 10.54 Bn |
| Mar 31, 2024 | 14.13 Bn |
| Dec 31, 2023 | 14.15 Bn |
| Jul 2, 2023 | 10.08 Bn |
| Apr 2, 2023 | 7.70 Bn |
| Jan 1, 2023 | 27.24 Bn |
| Oct 2, 2022 | 8.63 Bn |
| Jul 3, 2022 | 9.44 Bn |
| Apr 3, 2022 | 9.94 Bn |
| Jan 2, 2022 | 10.22 Bn |
| Oct 3, 2021 | 6.87 Bn |
| Jul 4, 2021 | 7.17 Bn |
| Apr 4, 2021 | 6.54 Bn |